Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC. EV+P continues to show superior efficacy and durable responses in previously untreated locally advanced or metastatic UC. Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial. Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study. Dr. Daneshmand provides overviews and updates from three clinical trials involving cretostimogene for high-risk NMIBC. The interim analysis of the RETAIN-2 trial demonstrated a 46% pT0 rate among those undergoing cystectomy. New research evaluated the efficacy and safety of durvalumab with intravesical gem/doce in a cohort from ADAPT-BLADDER. Nivolumab demonstrated sustained DFS benefits across all patients with MIBC and in prior NAC subgroups. Dr. Ciuro previews the potential practice-changing research in prostate, bladder, and kidney cancers from ASCO GU 2025. Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CheckMate 274, NIAGRA, and more. This new research shows no link between patient BMI and NMIBC recurrence, stage progression, or grade progression. Dr. Geynisman shares insights on the feasibility of bladder-sparing approaches in treating muscle-invasive bladder cancer. Using mpMRI before TURBT may be beneficial for patients with suspected MIBC. Dr. Murray and Laura Bauer share their experiences treating patients with UTUC using mitomycin gel. Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges. Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program. Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice. Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors. The indication for SG as a treatment for patients with pretreated aUC will be officially withdrawn by Gilead. Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.